6 RESULTS
COMMENT I was saddened to hear that the world of AD, and all of us who knew Peter, had lost him. His early discoveries regarding the cholinergic system were highly influential in leading to the development of cholinergic therapies. His work and these drugs ...
COMMENT These are exciting results. They strongly support target engagement, suggest a dosing strategy, and suggest efficacy on clinical measures. The challenges with randomization raise questions that must be solved with future trials. This is a strong Phase 2 ...
COMMENT A few points are worth making: The analysis of the amyloid imaging by genotype was prespecified as part of the primary outcome, and this study can be seen as meeting its prespecified primary outcome measure. The increased serum Aβ1-42 correlated with ...
COMMENT In response to Lon Schneider: Agitation is one of the most disabling features of AD and other dementias, compromising the quality of life of both patients and care providers. It is a common cause of institutionalization in the United States and is ...
COMMENT Phase 2A Trial of Bexarotene in Patients with Alzheimer’s Disease Cramer and colleagues (Cramer et al., 2012) reported the rapid reduction of soluble amyloid, as well as amyloid plaques, in two species of transgenic mice. The effect occurred over a period ...
COMMENT The AD 2000 collaborative group have studied the cost-effectiveness of donepezil in the UK. In their study, donepezil did not delay nursing home placement, and since this is the major cost driver of Alzheimer's disease (AD), the agent did not reduce ...
